The pathogenetic role of undifferentiated connective tissue dysplasia in congenital nephropathies in children

Victor Roller

doi:10.52673/18570461.26.1-80.09

Autori

Victor Roller Universitatea de Medicină și Farmacie Nicolae Testemițanu din Chișinău https://orcid.org/0000-0002-3003-6886

DOI:

https://doi.org/10.52673/18570461.26.1-80.09

Cuvinte cheie:

biomarkeri, copii, displazie, țesut conjunctiv

Rezumat

Anomaliile congenitale ale țesutului conjunctiv reprezintă una dintre cele mai frecvente malformații congenitale ale sistemului urinar întâlnit în populația pediatrică. În același timp, unul dintre principalii factori patogenetici ai afectării funcției renale în nefropatiile congenitale este hipoxia, totodată, hipoxia este considerată unul dintre factorii de bază care afectează metabolismul țesutului conjunctiv, ceea ce creează un cerc vicios. De aceea, pentru a facilita diagnosticul, stadializarea, urmărirea pe termen lung și prevenirea complicațiilor, sunt necesare studii aprofundate privind evaluarea unor biomarkeri legați de fiziopatologia țesutului conjunctiv. Lucrarea reprezintă o analiză complexă retrospectivă şi prospectivă a unui lot, constituit din 100 de pacienţi rezolvați chirurgical cu malformații reno-urinare în perioada 2013–2025. Analiza prospectivă a fișelor de observații a fost efectuată la 35 de pacienți cu hidronefroză congenitală, la 45 – cu reflux vezico-ureteral și la 20 – cu megaureterohidronefroză. Evaluarea nivelurilor de PCE(BChE), dar și a altor biomarkeri, cum ar fi proteinele totale, analiza funcționalității N-acetil-beta-D-glucozaminidazei (NAG) serice, pot oferi informații valoroase despre prognosticul pacienților în diverse situații clinice și poate contribui la îmbunătățirea acurateței prognostice și la instituirea unor formule noi de tratament patogenetic eficient la copiii cu reflux vezicoureteral (RVU) și anomalii congenitale de dezvoltare, pe fondul displaziei țesutului conjunctiv. Sunt necesare studii aprofundate orientate spre reducerea incidenței displaziei țesutului conjunctiv în nefropatiile congenitale la copii.

Referințe

1. Kryganova, T.A.; Aksenova, M.Ye.; Dlin, V.V. Puzyrno-mochetochnikovyy reflyuks i yego oslozhneniya u detey v zavisimosti ot stepeni vyrazhennosti displazii soyedinitel’noy tkani, in: Ros Vestn Perinatol Pediat. 2016; 4:93-97. https://doi.org/10.21508/1027-4065-2016-61-4-93-97

2. Povshedna, T.Yu.; Shevchuk, D.V.; Korniychuk, N.M. The role of timely treatment of congenital malformations of the urinary system in the prevention of chronic renal failure in children, in: Biol Res, 2015, 1:423-429.

3. Semyanchuk, V.B. Prevalence of manifestations of undifferentiated connective tissue dysplasia in children of Prykarpattia, patients with bronchial asthma, in: Act Prob Mod Med, 2015, 15(2):149-154.

4. Lukina, T.S. Evaluation of the oxyproline marker and its value in women with undiferentiated connective tissue dysplasia, in: Mod Med, 2015, Top Issues 6-7(41):6-10.

5. Maydannyk, V.H.; Burlaka, Ye.A. State of metabolic hypoxic disorders in diabetic nephropathy in children, in: Exp Clin Physiol Biochem, 2015; 4:47-55. https://doi.org/10.25040/ecpb2015.04.047

6. Sakashita, M.; Tanaka, T.; Inagi, R. Metabolic Changes and Oxidative Stress in Diabetic Kidney Disease, in: Antioxidants (Basel). 2021, Jul 19;10(7):1143. https://doi.org/10.3390/antiox10071143

7. Jovičić, S.M. Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives, in: International Journal of Immunopathology and Pharmacology. 2024;38. https://doi.org/10.1177/03946320241289013

8. Markuskova, L.; Javorova, Rihova Z.; Fazekas, T., et al. Serum butyrylcholinesterase as a marker of COVID-19 mortality: Results of the monocentric prospective observational study, in: Chem Biol Interact. 2023;381:110557. https://doi.org/10.1016/j.cbi.2023.110557

9. Kadurina, T.I.; Gnusayev, S.F.; Arsent’yev, V.G. Chast’ 2. Poliorgannyye narusheniya pri displazii soyedinitel’noy tkani u detey. Algoritmy diagnostiki. Taktika vedeniya. Proyekt rossiyskikh rekomendatsiy, in: Meditsinskiy vestnik Severnogo Kavkaza, 2016;2(2):239-263. https://doi.org/10.14300/mnnc.2016.11050

10. Dorota, Stefanicka-Wojtas; Donata, Kurpas. Personalised Medicine – Implementation to the Healthcare System in Europe (Focus Group Discussions), in: J Pers Med. 2023, Feb 21;13(3):380. https://doi.org/10.3390/jpm13030380

11. Kohl, S.; Avni, F.E.; Boor, P.; Capone, V., et al. Definition, diagnosis and clinical management of non-obstructive kidney dysplasia: a consensus statement by the ERKNet Working Group on Kidney Malformations, in: Nephrol Dial Transplant. 2022, Nov 23;37(12):2351-2362. https://doi.org/10.1093/ndt/gfac207

12. Shcherbo, S.N.; Shcherbo, D.S. Laboratornaya diagnostika kak osnova meditsiny 5P, in: Vestnik RGMU. 2019; (1): 5-14. https://doi.org/10.24075/vrgmu.2018.095

13. Mahmoud, A.H.; Talaat, I.M.; Tlili, A. and Hamoudi, R. Congenital anomalies of the kidney and urinary tract, in: Front. Med. 2024; 11:1384676. https://doi.org/10.3389/fmed.2024.1384676

14. Uitto, J.; Lichtenstein, J.R. Defects in the biochemistry of collagen in diseases of connective tissue, in: J Invest Dermatol. 1976, Feb;66(02):59-79. https://doi.org/10.1111/1523-1747.ep12481404

15. Simsek B.; Karacaer, O.; Karaca, I. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview, in: Chinese Medical Journal 117(2):291-295, 2004.

16. Fischbach, F. Urine Hydroxyproline, in: A Manual of Laboratory and Diagnostic Tests. Lippincott Williams & Wilkins, USA, 8 ed. 2009, 278-279.

17. Chen, Y.; Dai, R.; Cheng, M., et al. Status and role of the ubiquitin-proteasome system in renal fibrosis, in: Biomed Pharmacother. 2024 Sep;178:117210. https://doi.org/10.1016/j.biopha.2024.117210

18. Xia, G.; Guo, Y.; Zhang, J.; Han, M.; Meng, X.; Lv J. An Overview of the Deubiquitinase USP53: A Promising Diagnostic Marker and Therapeutic Target, in: Curr Protein Pept Sci. 2024;25:708-18. https://doi.org/10.2174/0113892037292440240518194922

19. Shaid; S.; Brandts, C.H.; Serve, H.; Dikic, I. Ubiquitination and selective autophagy, in: Cell Death Differ. 2013;20:21-30. https://doi.org/10.1038/cdd.2012.72

20. Chiang, C.-K.; Hsu, S.-P.; Wu C.-T., et al. Endoplasmic Reticulum Stress Implicated in the Development of Renal Fibrosis, in: Mol. Med. 2011; 17: 1295-1305. https://doi.org/10.2119/molmed.2011.00131

21. Chen, X.; Yong, H.; Chen, M., et al. TRIM21 attenuates renal carcinoma lipogenesis and malignancy by regulating SREBF1 protein stability, in: J Exp Clin Cancer Res. 2023;42:34. https://doi.org/10.1186/s13046-022-02583-z

22. Labbadia, J., Morimoto, R.I. The biology of proteostasis in aging and disease, in: Annu Rev Biochem. 2015;84:435-64. https://doi.org/10.1146/annurev-biochem-060614-033955

23. Chen, J.H.: Wu, C.H.: Chiang, C.K. Therapeutic Approaches Targeting Proteostasis in Kidney Disease and Fibrosis, in: Int J Mol Sci. 2021 Aug 12;22(16):8674. https://doi.org/10.3390/ijms22168674

24. Navarro-Betancourt, J.R.; Cybulsky, A.V. The IRE1α pathway in glomerular diseases: The unfolded protein response and beyond, in: Front Mol Med. 2022 Sep 26;2:971247. https://doi.org/10.3389/fmmed.2022.971247

25. Nangaku, M. Mechanisms of Tubulointerstitial Injury in the Kidney: Final Common Pathways to End-stage Renal Failure, in: Intern. Med. 2004; 43:9-17. https://doi.org/10.2169/internalmedicine.43.9

26. Inoue, T.; Maekawa, H.; Inagi, R. Organelle crosstalk in the kidney, in: Kidney Int. 2019; 95:1318-1325. https://doi.org/10.1016/j.kint.2018.11.035

27. Kurts, C.; Panzer, U.; Anders, H.-J.; Rees, A.J. The immune system and kidney disease: Basic concepts and clinical implications, in: Nat. Rev. Immunol. 2013;13: 738-753. https://doi.org/10.1038/nri3523

28. Tampe, D.; Zeisberg, M. Potential approaches to reverse or repair renal fibrosis. in: Nat. Rev. Nephrol. 2014;10:226-237. https://doi.org/10.1038/nrneph.2014.14